Anthony S. Gibney Purchases 50,000 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Anthony S. Gibney acquired 50,000 shares of the business’s stock in a transaction on Friday, May 16th. The stock was acquired at an average price of $4.90 per share, with a total value of $245,000.00. Following the acquisition, the insider now owns 58,452 shares in the company, valued at $286,414.80. The trade was a 591.58% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $5.96 on Thursday. The stock has a market capitalization of $299.60 million, a P/E ratio of -3.45 and a beta of 0.43. The company has a 50 day moving average price of $5.83 and a 200 day moving average price of $7.47. Aura Biosciences, Inc. has a fifty-two week low of $4.35 and a fifty-two week high of $12.38.

Aura Biosciences (NASDAQ:AURA) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.08). Research analysts forecast that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aura Biosciences

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of Aura Biosciences by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock worth $8,327,000 after purchasing an additional 3,972 shares during the period. Wellington Management Group LLP boosted its position in shares of Aura Biosciences by 12.6% during the 4th quarter. Wellington Management Group LLP now owns 131,054 shares of the company’s stock worth $1,077,000 after purchasing an additional 14,662 shares during the period. American Century Companies Inc. boosted its position in shares of Aura Biosciences by 33.9% during the 4th quarter. American Century Companies Inc. now owns 47,701 shares of the company’s stock worth $392,000 after purchasing an additional 12,081 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Aura Biosciences by 76.4% during the 4th quarter. JPMorgan Chase & Co. now owns 94,386 shares of the company’s stock worth $776,000 after purchasing an additional 40,884 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Aura Biosciences by 25.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 365,824 shares of the company’s stock valued at $3,007,000 after buying an additional 73,062 shares during the period. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Citigroup reissued an “outperform” rating on shares of Aura Biosciences in a research note on Wednesday, March 26th. JMP Securities set a $19.00 price target on shares of Aura Biosciences in a research note on Wednesday, March 26th. HC Wainwright set a $25.00 price target on shares of Aura Biosciences in a research note on Tuesday, March 25th. Finally, Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $22.75.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.